Trials / Completed
CompletedNCT00773929
Safety Study of TAK-593 Given Orally in Subjects With Nonhematologic Advanced Cancer
A Multicenter Phase I Clinical and Pharmacokinetic Study of Oral TAK-593 in Subjects With Nonhematologic Advanced Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Millennium Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and toxicity profile of TAK-593 and determine the maximum tolerated dose of TAK-593.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TAK-593 | Tablets of TAK-593 investigational drug for oral administration, tablets in 2 strengths: 1 mg and 4 mg tablets. Administration will initially be 4 mg, once a day and transition to 2 mg BID schedule dependant on safety |
Timeline
- Start date
- 2009-01-01
- Primary completion
- 2010-01-01
- Completion
- 2010-04-01
- First posted
- 2008-10-16
- Last updated
- 2010-04-27
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00773929. Inclusion in this directory is not an endorsement.